News

Sorrento is expected to utilise its proprietary antibody library technology to identify fully human antibodies for the neutralisation of Staph-specific signaling peptides that control bacterial virulence. A research

The company said that with this acquisition, it becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings.

AMR101 is an ultra-pure omega-3 form being developed with ethyl ester of eicosapentaenoic acid (ethyl-EPA). Numerous independent studies have demonstrated the safety, tolerability and efficacy of ethyl-EPA in

Ceplene is indicated for remission maintenance therapy and prevention of relapse in adult patients with acute myeloid leukemia (AML). In a multicenter study, Ceplene met its primary endpoint

The study has achieved its primary clinical endpoint of a statistically improvement in International Prostate Symptom Score (IPSS) for patients treated with PRX302 versus subjects receiving placebo. In

In May 2009, the company had announced that the efficacy portion of its Phase 3 Freedom-301 clinical study of Levadex met all four primary endpoints. The company had

The manufacturing facility is now ready to offer contract manufacturing services which could commence following the manufacture of Multikine. Reportedly, the phase III clinical trial with Multikine will

As per the agreement, Sanofi Pasteur has acquired worldwide rights to KaloBios’ technology for all disease indications related to Pa infections, except cystic fibrosis and bronchiectasis, which Sanofi

The study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, outpatient dose regimen-finding study. It will enroll approximately 200 patients who meet the criteria for RA with